Drugs / IMAB027
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02054351 | Feb 2014 → Oct 2015 | ovarian cancer | Ganymed Pharmaceuticals GmbH | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMAB027 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02054351 ↗ |
| Action | Deplete | “to kill cancer cells by antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity” NCT02054351 ↗ |
| Modality | Monoclonal antibody | “IMAB027 is a monoclonal antibody that binds to CLDN6.” NCT02054351 ↗ |
| Target | CLDN6 | “binds to CLDN6” NCT02054351 ↗ |